Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study
Two compounds binding the same receptor do not necessarily produce the same downstream profile the binding conformation determines which coupled signaling pathways are preferentially activated
Pharmaceutical companies are expected to continue ramping up production, which should make brand-name prescriptions easier to find at local pharmacies
J.McGarrityL
US$ 21.60
US$ 27.69
US$ 29.20
US$ 27.30
US$ 25.76
